Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a new multivalent pneumococcal vaccine called PG4 in healthy infants. This vaccine is being compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC. The study aims to see how well the new vaccine helps fight germs that cause pneumonia, meningitis, and ear infections, and whether it provides additional protection against pneumococcal disease compared to the existing vaccine. The study includes three groups of infants based on age and location. Group 1 involves about 3000 infants who are 2 months old and will receive either PG4 or 20vPnC shots into the left thigh muscle at 2, 4, 6, and 12 to 15 months of age. Groups 2 and 3, with smaller numbers of infants from outside the United States aged 2 to 6 months, will receive different schedules of PG4 or 20vPnC either intramuscularly or under the skin. Each infant will be randomly assigned to one of the vaccine types and administration methods. Participants will be involved in the study for about 12 to 19 months depending on their group. During this time, infants will attend six clinic visits and one phone call, where parents or guardians will be asked about any side effects experienced. Blood samples will be collected three times to measure the immune response through proteins that fight the pneumococcal disease germs. The study also monitors local and systemic reactions, adverse events, and serious adverse events following vaccination.
Actively Recruiting
Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.
Actively Recruiting
Researchers are conducting a Phase 2 randomized, double-masked, vehicle-controlled study to evaluate the safety and effectiveness of DFL24498 topical ophthalmic solution compared to a vehicle solution in adults with dry eye disease. Approximately 417 participants aged 18 years or older will be enrolled across multiple sites in the US. The study aims to understand how the treatment affects dry eye symptoms and eye health over 16 weeks. Participants will be randomly assigned to receive either DFL24498 or a vehicle solution, both administered as one drop in each eye four times daily for 12 weeks. The study includes three periods within the total 16 weeks, including treatment and follow-up phases. The treatments are applied topically to the eyes under controlled conditions to compare their effects. During the study, participants will undergo assessments such as corneal fluorescein staining using the National Eye Institute scale, symptom evaluations with the Symptom Assessment in Dry Eye questionnaire, tear production tests, and conjunctival staining. Safety will be monitored through reports of adverse events up to week 14. Visual acuity and other ocular measurements will be regularly checked to monitor treatment impact and participant health throughout the study.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether adding biennial contrast-enhanced mammography CEM to annual 3D mammography tomosynthesis improves breast cancer detection with minimal increase in false positives in women with a personal history of breast cancer. The study focuses on maintaining or improving cancer detection rates while reducing unnecessary recalls, aiming to enhance screening accuracy. This is a prospective clinical trial led by Wendie Berg to assess these outcomes in a screening context. Participants will receive a baseline CEM exam combined with their routine annual 3D mammography DBT, followed by additional CEM exams at 24 and 48 months after the baseline. Throughout the study, they will continue their usual annual DBT exams. Two radiologists will independently review pairs of exams to compare the detection rates and false-positive recalls of CEM combined with DBT versus DBT alone. During the study, participants will undergo regular breast cancer screening with combined CEM and DBT exams as described. Researchers will measure cancer detection rates, false-positive recall rates, and positive predictive values at 24, 48, and 62 months. The study monitors safety and effectiveness outcomes while participants continue their routine care, with the study lasting until April 2031.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are evaluating combinations of targeted drugs in people with advanced non-small cell lung cancer that has spread and shows specific changes in the EGFR and MET genes. This phase II Lung-MAP trial focuses on patients whose cancer has progressed after treatment with osimertinib and aims to compare the effectiveness of combining capmatinib, osimertinib, and ramucirumab. The study also investigates safety, response rates, and survival outcomes while collecting biological samples for further analysis. Participants are randomly assigned to one of two groups. One group receives capmatinib and osimertinib as oral medications plus ramucirumab given intravenously, while the other group receives only capmatinib and osimertinib orally. During the trial, patients undergo regular CT or MRI scans and blood sample collections to monitor their disease and treatment effects. The study includes detailed assessments of tumor responses and side effects over time. Throughout the trial, participants will have scans and blood tests at scheduled intervals to assess disease progression and treatment impact. Researchers will monitor progression-free survival as the main outcome, along with response duration and toxicity. Blood samples are also collected to study circulating tumor DNA. The study continues up to three years, with ongoing safety and efficacy evaluations. Participants must meet specific health criteria and provide informed consent before joining.
Actively Recruiting
Diabetic foot ulcers DFU are a common and serious complication for people with type 2 diabetes, often leading to hospitalization and amputation. This research investigates whether DFUs with a history of biofilm infection heal with weakened skin barrier function and if this impaired healing, shown by high trans-epidermal water loss TEWL, increases the chance of wound recurrence. The study also explores the molecular mechanisms behind biofilm-related damage to skin barrier integrity in DFU patients. In this observational study, 405 patients with clinically diagnosed DFUs suspected of infection will be enrolled. Researchers will collect wound swabs for culture, take digital images of wounds, and perform assessments including health surveys and pain scales. Tests such as transcutaneous oxygen measurement, ankle-brachial index, and hemoglobin A1c will be conducted as needed. Tissue samples from the wound area will be collected to study biofilm presence. Participants will be followed for up to 16 weeks or until their wound closes. Participants will undergo regular evaluations including wound site checks and questionnaires on wound impact and pain. Monitoring involves reviewing medical records and contacting patients or care facilities to confirm wound closure. The primary outcomes being measured are biofilm infection levels at 16 weeks and TEWL at 12 weeks. This thorough monitoring aims to understand how biofilm infection affects wound healing and recurrence in diabetic foot ulcers.
Actively Recruiting
Researchers are evaluating whether a virtual exercise program can be effectively delivered to cancer patients receiving chemotherapy. The study aims to help patients maintain strength and reduce fatigue caused by cancer treatments, which can interfere with daily activities and work. This supportive care trial focuses on patients with various localized malignant solid tumors undergoing curative-intent chemotherapy. Participants follow a supervised exercise program via telehealth video calls that include resistance and aerobic exercises. They complete supervised aerobic and resistance sessions twice a week and additional unsupervised aerobic exercises weekly, continuing until the end of their chemotherapy or up to six months. Patients receive exercise equipment such as a stationary bike, dumbbells, resistance bands, and wear an accelerometer to monitor activity. During the study, researchers monitor exercise session completion, patient retention, and physical function changes using tests like the 6 Minute Walk Test and grip strength. Patients also complete questionnaires and interviews about their physical activity and quality of life. Follow-up assessments occur four weeks and three months after the intervention, with total participation lasting up to six months or until chemotherapy completion.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of an investigational eye drop solution called Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, compared to a placebo vehicle solution in adults experiencing eye redness due to minor irritations. The study targets adults with ocular redness and focuses on measuring changes in redness after treatment. It is a Phase 3, randomized, double-blind clinical trial sponsored by Alcon Research. Participants will receive a single dose of the study treatment, one drop in each eye on Day 1. The study includes two groups one receiving the investigational Apraclonidine solution and the other receiving a vehicle placebo. The treatment is given during an in-office visit, and eye redness is assessed before and after instillation at specific timepoints on Day 1 and Day 2. Participants are expected to attend three in-office visits over about one week. Assessments include investigator-rated redness scores at baseline and at several times after treatment, including 1 minute, 15 minutes, 14 hours, and 16 hours post-instillation. Safety and efficacy are monitored through these evaluations. The total study period covers from treatment through follow-up assessments, concluding around one week after the first dose.
1-10 of 19
1